The development of type-1 autoimmune hepatitis after chronic hepatitis C (HCV) clearance by direct-acting antivirals (DAA).

We present the case of a 72-year-old female in follow-up for chronic hepatitis due to hepatitis C virus (HCV) genotype 1b, with a liver stiffness measurement estimated by transient elastography in 2015 of 17 Kp and type 2 diabetes mellitus. She was treated daily with ledipasvir 90 mg and sofosbuvir 400 mg for 12 weeks. In March 2016, she achieved a sustained virological response (SVR) after 12 weeks and 24 weeks. She had a positive determination of antinuclear antibodies 7.9 in 2014.